overactive%20bladder
OVERACTIVE BLADDER

Overactive bladder or non-neurogenic overactive bladder is a syndrome characterized by urinary urgency, frequency, nocturia and urgency incontinence.
It is not a disease but a symptom complex that generally is not a life-threatening condition. It is also known as bladder spasms.
Urgency is the complaint of sudden, compelling desire to pass urine that is difficult to deny. It is considered a hallmark symptom of overactive bladder.
Frequency is usually micturition of >7 episodes during waking hours.
Nocturia is the interruption of sleep one or more times because of the need to void.
Urgency incontinence is the involuntary leakage of urine associated with a sudden compelling desire to void.

Drug Information

Indication: Symptomatic treatment of urgency, increased micturition frequency &/or urgency incontinence as may occur i...

Indication: Overactive bladder w/ symptoms of urge, urinary incontinence, urgency & frequency.

Indication: Symptomatic treatment of urge incontinence &/or increased urinary frequency & urgency.

Indication: Symptomatic treatment of urge incontinence &/or increased urinary frequency & urgency in patients w/ o...

Botox
clostridium botulinum toxin type A

Indication: Treatment of blepharospasm associated w/ dystonia, including benign essential blepharospasm, hemifacial spasm ...

Indication: Overactive bladder w/ symptoms of urinary urgency, frequency & urge incontinence.

Dysport
botulinum A toxin

Indication: Symptomatic treatment of focal spasticity of upper limbs in adults & dynamic equinus foot deformity in amb...

Toviaz
fesoterodine fumarate

Indication: Overactive bladder w/ symptoms of urge urinary incontinence, urgency & frequency.

Indication: Symptomatic relief of bladder instability associated w/ voiding in patients w/ uninhibited neurogenic or reflu...

Editor's Recommendations
Most Read Articles
14 Mar 2017
Asian prostate cancer patients may show a significant reduction in bone mineral density (BMD) 12 months after androgen deprivation therapy (ADT) with no difference between those on continuous combined androgen block (CAB) and those on gonadotropin-releasing hormone (GnRH) agonist monotherapy, a new study shows.